Welcome to our dedicated page for Castle Biosciences news (Ticker: CSTL), a resource for investors and traders seeking the latest updates and insights on Castle Biosciences stock.
Castle Biosciences, Inc. (symbol: CSTL) is a pioneering company specializing in diagnostic tests for a variety of cancers. Founded in 2008, Castle Biosciences has dedicated itself to advancing cancer care through objective and accurate testing. The company's primary mission is to provide physicians and patients with personalized, clinically actionable genomic information to facilitate more precise treatment decisions.
Castle Biosciences offers a range of diagnostic tests that assist doctors in the treatment of various cancers. Their current product portfolio includes tests for cutaneous melanoma, uveal melanoma, esophageal adenocarcinoma, mesothelioma, and glioma. Notably, their products include DecisionDx-Melanoma, DecisionDx-CMSeq, and DecisionDx-PRAME, all designed to provide vital information that can influence the course of cancer treatment.
The company is not just limited to its existing portfolio; it actively engages in research programs aimed at developing diagnostic tests for other under-served cancers, such as rectal cancer and soft tissue sarcoma. These initiatives underscore Castle Biosciences' commitment to addressing gaps in cancer diagnostics and improving patient outcomes.
Castle Biosciences collaborates closely with leading members of the oncology community to ensure that their tests are both innovative and clinically relevant. This collaboration spans the discovery, development, and practical utilization of their diagnostic tests, reinforcing their standing as a crucial player in the field of cancer diagnostics.
The company is currently in a robust financial condition, reflecting its successful commercialization efforts and consistent revenue growth. Recent achievements include expanding their test portfolio and forging strategic partnerships aimed at broadening their market reach and enhancing their technological capabilities.
For the latest updates and detailed information on Castle Biosciences, Inc. and its products, please visit their official website at www.castlebiosciences.com.
Pittsburgh Life Science Greenhouse announced that Castle Biosciences (CSTL) will acquire Cernostics, a company focused on spatial biology and AI-driven tissue biopsy analysis. The acquisition involves an initial payment of $30 million, with additional potential payments of up to $50 million based on performance metrics in 2022. Cernostics is known for its TissueCypher® Barrett's Esophagus Assay, which predicts the risk of high-grade dysplasia and esophageal cancer in Barrett's esophagus patients. The deal is expected to close by year-end 2021.
Castle Biosciences, Inc. (NASDAQ: CSTL) is set to release its financial results for the third quarter and nine months ended Sept. 30, 2021, after market close on Nov. 8, 2021. Management will hold a conference call and webcast at 4:30 p.m. Eastern time to discuss these results. The company focuses on innovative diagnostics aimed at improving disease management and patient outcomes, particularly in skin cancer diagnostics.
Castle Biosciences (Nasdaq: CSTL) has announced recent presentations at the 2021 Fall Clinical Dermatology Conference, showcasing advancements in dermatologic cancer gene expression profile (GEP) tests and a pipeline initiative for inflammatory skin conditions. The company demonstrated the capabilities of its DecisionDx-Melanoma test, which provides personalized risk predictions for melanoma patients. Additionally, Castle is developing a GEP test to guide therapy selection for moderate to severe psoriasis and atopic dermatitis, addressing a significant unmet clinical need.
Castle Biosciences, Inc. (CSTL) has announced the acquisition of Cernostics, Inc., enhancing its growth strategy with the TissueCypher® platform aimed at improving the diagnosis of esophageal cancer. This acquisition is expected to expand Castle's U.S. total addressable market by approximately $1 billion. The deal includes an initial payment of $30 million, with potential milestone payments of up to $50 million based on 2022 performance. The acquisition aligns with Castle's mission to utilize innovative technology for better patient outcomes in gastrointestinal diagnostics.
Castle Biosciences (NASDAQ: CSTL) announced that CEO Derek Maetzold will keynote the AZAdvances Life Science Innovation Showcase on October 6, 2021, during Arizona Bioscience Week, occurring from October 3-9. The event, presented by AZBio and the Arizona Commerce Authority, celebrates the state's bioscience industry and its commitment to patient care and innovation. Maetzold expressed pride in supporting future innovators through AZAdvances, which provides mentorship and funding.
Castle Biosciences (Nasdaq: CSTL) has secured approval from the New York State Department of Health for its DecisionDx® DiffDx™-Melanoma gene expression profile test. This test aims to aid dermatopathologists in diagnosing ambiguous melanocytic lesions. The approval expands the company's diagnostic offerings, which include myPath® Melanoma, enhancing the accuracy of melanoma management. Castle has previously received state approvals for other genomic tests, indicating a robust position in the dermatologic diagnostics market.
Castle Biosciences, Inc. (Nasdaq: CSTL) announced that its CEO, Derek Maetzold, and CFO, Frank Stokes, will present at the Virtual Wells Fargo Healthcare Conference on September 9, 2021, and the Baird Global Healthcare Conference on September 15, 2021. Live audio webcasts will be accessible on the company’s website, with replays available for two weeks after the events. Additionally, the company will hold one-on-one meetings during the Lake Street Capital Markets Best Ideas Growth Conference on September 14, 2021.
Castle Biosciences (NASDAQ: CSTL) has secured a five-year Federal Supply Schedule contract with the Veterans Health Administration (VHA) for its DecisionDx®-Melanoma test, effective from
Castle Biosciences (Nasdaq: CSTL) reported new insights on its skin cancer gene expression profile tests, DecisionDx-Melanoma and DecisionDx-SCC, at the 2021 AAD Summer Meeting. DecisionDx-Melanoma enhances risk prediction for melanoma metastasis using a 31-gene profile, significantly improving prognostication beyond traditional staging methods. DecisionDx-SCC, a 40-gene test, identifies high-risk cutaneous squamous cell carcinoma cases, aiding in tailored patient management. Both tests show independent, significant predictive value, promising better patient outcomes and personalized treatment decisions.
FAQ
What is the current stock price of Castle Biosciences (CSTL)?
What is the market cap of Castle Biosciences (CSTL)?
What does Castle Biosciences specialize in?
When was Castle Biosciences founded?
What types of cancer does Castle Biosciences have tests for?
What are some of Castle Biosciences' notable products?
Is Castle Biosciences involved in research for new diagnostic tests?
Where can I find more information about Castle Biosciences and its products?
What is the primary mission of Castle Biosciences?
Does Castle Biosciences collaborate with other entities?
What is Castle Biosciences' financial condition?
How does Castle Biosciences contribute to cancer care?
